Targeted therapy for relapsed B-cell leukemia and lymphoma using CAR T-cells
Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL
This study is testing a new treatment for adults with tough-to-treat B-cell leukemia and lymphoma, using special CAR T-cells along with a unique method to help make the treatment safer and more effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Actinium Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (New York, UNITED STATES) |
| Project ID | NIH-10892773 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). It combines a targeted therapy using CD19-directed CAR T-cells with a novel conditioning treatment that aims to reduce side effects while enhancing the effectiveness of the CAR T-cell therapy. The study focuses on using a specific antibody labeled with iodine to deplete certain immune cells before administering the CAR T-cells, potentially improving patient outcomes. Patients will be monitored for both efficacy and safety throughout the treatment process.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have relapsed or refractory B-ALL or DLBCL.
Not a fit: Patients with other types of cancers or those who are not relapsed or refractory may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with difficult-to-treat B-cell malignancies.
How similar studies have performed: Previous research has shown promising results with CAR T-cell therapies, but this specific approach using targeted lymphodepletion is novel.
Where this research is happening
New York, UNITED STATES
- Actinium Pharmaceuticals, INC. — New York, United States (Active)
Researchers
- Principal investigator: Desai, Avinash — Actinium Pharmaceuticals, INC.
- Study coordinator: Desai, Avinash
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.